Clinical Trial Update: Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety, feasibility, and immunogenicity of DCP-001, an allogeneic cell-based vaccine, in patients with high-grade serous o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• DCP-001

Snippet

Sponsor: University Medical Center Groningen | Conditions: Ovarian Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING